))
Leukemia Edition: Top Headlines for Week of July 31, 2023
Manage episode 407442261 series 3560281
Contenuto fornito da Healio. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Healio o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more. Read the full coverage here:
FDA approves Vanflyta for newly diagnosed acute myeloid leukemia
VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL
Community affluence, insurance mediate CV mortality among Black, white cancer survivors
VIDEO: MOLTO study probes combination therapy in Richter syndrome
Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome
References:
ASCO Annual Meeting ASCO Annual Meeting Press Release Press Release Sung H, et al. Int J Epidemiol. 2023;doi:10.1093/ije/dyad097.
120 episodi
Condividi
